Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1622 1629
This examiner grants 34% of resolved cases
Chris E Simmons handles a large volume of cases in Art Unit 1612, part of Tech Center 1600. Across 684 resolved cases, the examiner maintains an allowance rate of 34.1%. This suggests a rigorous examination standard. An interview lift of 19.4% indicates that direct engagement can improve the odds of allowance. The median time to allowance is 1508 days, reflecting a prolonged prosecution period.
Practitioners should be prepared for a detailed effort to secure a patent, though interviews provide a 19.4% advantage. The 34.1% allowance rate is the primary baseline for applications in Art Unit 1612. With 684 resolved cases, the examiner has a well-established track record in Tech Center 1600. Successful outcomes typically require 1508 days to reach allowance. Strategy should focus on using the 19.4% lift to overcome rejections during this 1508-day cycle.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18255518 | RESTORATION OF MOTOR FUNCTION POST-NEUROLOGICAL INJURY USING PSYCHEDELICS | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17597339 | COMPOSITIONS AND METHODS USING TRIGONELLINE TO PRODUCE INTRACELLULAR NAD+ | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 17378839 | METHOD FOR PREVENTING OR TREATING SKIN DISORDERS AND CONDITIONS | Non-Final OA | BUDDHIST TZU CHI MEDICAL FOUNDATION |
| 17760621 | IDENTIFICATION OF COMPOUNDS THAT INHIBIT STRESS GRANULE FORMATION AND TAU AGGREGATION BY TARGETING TIAI | Non-Final OA | The Trustees Of Columbia University In The City Of New York |
| 17309435 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | Final Rejection | Board of Regents of the University of Nebraska |
| 17637004 | METHODS FOR ENHANCING DNA DAMAGE AND APOPTOSIS OF LEUKEMIC CELLS | Non-Final OA | Thomas Jefferson University |
| 18019627 | COMPOSITIONS FOR ALTERING A MICROGLIAL CELL, AND METHODS OF USE THEREFORE | Non-Final OA | The Children's Medical Center Corporation |
| 17614437 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | Final Rejection | Conservatoire National des Arts et Métiers (CNAM) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy